DTIL · Precision Biosciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $34.26M | $68.70M | $48.73M | $25.10M | $115.53M | $24.29M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $54.17M | $59.56M | $53.38M | $83.94M | $115.24M | $98.06M |
| SG&A | $32.24M | $35.30M | $39.09M | $41.52M | $39.69M | $36.05M |
| Total Operating Expenses | $86.41M | $94.86M | $92.46M | $125.46M | $154.93M | $134.11M |
| D&A | $1.47M | $3.40M | $6.82M | $7.80M | $8.98M | $8.78M |
| Operating Income | ($52.15M) | ($26.16M) | ($43.74M) | ($100.37M) | ($39.40M) | ($109.83M) |
| Interest Expense | $1.78M | $1.78M | $2.23M | $1.11M | $132.0K | - |
| Income Tax | $0 | - | - | - | - | $23.0K |
| Net Income | ($45.72M) | $7.17M | ($61.32M) | ($111.64M) | ($30.60M) | ($109.01M) |
| EPS - Basic | ($3.56) | $1.05 | ($15.96) | ($15.60) | - | - |
| EPS - Diluted | ($3.56) | $1.04 | ($15.96) | ($15.60) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.82M | $85.90M | $116.68M | $189.58M | $143.66M | $89.80M |
| Accounts Receivable | $0 | $229.0K | $901.0K | $720.0K | $488.0K | $10.00M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $296.0K | $1.31M | $2.97M | $1.23M | $1.14M | $792.0K |
| Current Assets | $118.74M | $94.99M | $136.36M | $199.10M | $161.75M | $105.56M |
| Total Assets | $154.42M | $136.39M | $159.78M | $238.17M | $211.50M | $150.16M |
| Current Liabilities | $8.91M | $14.98M | $49.99M | $59.66M | $35.98M | $42.83M |
| Long-term Debt | - | - | - | $22.22M | $2.48M | - |
| Total Liabilities | $62.17M | $80.00M | $140.92M | $177.74M | $120.33M | $105.73M |
| Stockholders' Equity | $92.25M | $56.39M | $18.86M | $60.43M | $91.17M | $44.42M |
| Retained Earnings | ($528.19M) | ($482.46M) | ($489.63M) | ($428.31M) | ($316.68M) | ($286.07M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($65.84M) | ($58.45M) | ($84.11M) | ($45.75M) | ($10.85M) | ($87.39M) |
| Investing Cash Flow | ($634.0K) | ($215.0K) | $5.83M | ($3.32M) | ($5.80M) | ($5.03M) |
| Financing Cash Flow | $95.16M | $50.45M | $5.39M | $94.98M | $70.52M | $1.33M |
| CapEx | $85.0K | $250.0K | $1.96M | $3.32M | $5.05M | $5.03M |
| Free Cash Flow | ($65.93M) | ($58.70M) | ($86.07M) | ($49.07M) | ($15.91M) | ($92.42M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -152.2% | -38.1% | -89.8% | -399.9% | -34.1% | -452.2% |
| EBITDA margin | -147.9% | -33.1% | -75.8% | -368.8% | -26.3% | -416.1% |
| Net margin | -133.4% | 10.4% | -125.8% | -444.8% | -26.5% | -448.9% |
| Free cash flow margin | -192.4% | -85.4% | -176.6% | -195.5% | -13.8% | -380.6% |
| FCF / Net income | 1.44 | -8.19 | 1.40 | 0.44 | 0.52 | 0.85 |
| R&D / Revenue | 158.1% | 86.7% | 109.5% | 334.4% | 99.7% | 403.8% |
| SG&A / Revenue | 94.1% | 51.4% | 80.2% | 165.5% | 34.4% | 148.5% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -29.6% | 5.3% | -38.4% | -46.9% | -14.5% | -72.6% |
| Return on equity | -49.6% | 12.7% | -325.1% | -184.7% | -33.6% | -245.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 |
| Quick ratio | 13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 |
| Cash ratio | 12.43 | 5.73 | 2.33 | 3.18 | 3.99 | 2.10 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.37 | 0.03 | - |
| Debt / Assets | - | - | - | 0.09 | 0.01 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -29.3x | -14.7x | -19.6x | -90.3x | -298.5x | - |
| Equity multiplier | 1.67 | 2.42 | 8.47 | 3.94 | 2.32 | 3.38 |
| Liabilities / Assets | 0.40 | 0.59 | 0.88 | 0.75 | 0.57 | 0.70 |
| Efficiency | ||||||
| Asset turnover | 0.22 | 0.50 | 0.30 | 0.11 | 0.55 | 0.16 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 0d | 1d | 7d | 10d | 2d | 150d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 3.7x | - | - | - | - |
| P / B | 0.6x | 0.5x | 2.2x | 34.7x | - | - |
| P / S | 1.6x | 0.4x | 0.9x | 83.5x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -50.1% | 41.0% | 94.1% | -78.3% | 375.7% | -97.7% |
| Revenue CAGR (3y) | 10.9% | -15.9% | 26.1% | -71.4% | - | - |
| Revenue CAGR (5y) | 7.1% | -42.3% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -99.3% | 40.2% | 56.4% | -154.7% | 64.1% | -129.2% |
| Net income growth (YoY) | - | - | 45.1% | -264.8% | 71.9% | -136.8% |
| EPS growth (YoY) | - | - | -2.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -12.3% | 31.8% | -75.4% | -208.5% | 82.8% | -40.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 63.6% | 199.0% | -68.8% | -33.7% | 105.2% | -67.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$34.26M totalOperating Segment$34.26M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.59
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing PRECISION BIOSCIENCES INC against the 5 most active filers in the same SIC group.